Antipyretic TRIZ Cases

Cage-type THGP octamer dissolves rapidly in water while maintaining neutral pH, eliminating the need for separate neutralization steps during administration.

IL-10 plasma concentration stratifies systemic lupus erythematosus patients to reduce corticosteroid requirements and improve therapeutic reliability.

Antibodies targeting specific TLR3 residues reduce cytokine production by over 50%, addressing insufficient inhibitory potency in existing antagonists.

Filipendula ulmaria extracts reduce hyperalgesia by inhibiting COX enzymes, avoiding neurological side effects of psychoactive medications.

Polyacrylamide hydrogel forms a stable sub-synovial layer within joints.

Bifidobacterium breve strain DSM 32583 enhances interleukin-10 expression in subjects.

Junctional protein modulators increase skin permeability to deliver high molecular weight agents without harsh solvents.

A topical composition using Phellodendron bark extract to cool skin and reduce heat.

Multi-strain Lactobacillus preparation overcomes transient therapeutic effects by establishing sustained vaginal niche colonization.

High-affinity humanized antibodies resolve low specificity of conventional inhibitors by blocking GM-CSF signaling pathways.

Phosphorylated dendrimers activate monocytes to reduce inflammation while avoiding tissue toxicity and high costs of conventional therapies.

Targeting the S100A9-TLR2 interaction reduces inflammatory responses without toxic side effects from traditional arthritis drugs.

A synthetic polypeptide composition mobilizes stem cells to arthritic sites and inhibits chondrocyte apoptosis.

Quinuclidinone derivatives use ester prodrugs and deuterium enrichment to resolve the contradiction between intravenous efficacy and oral accessibility.

Chrexanthomycins block TRPV1 channels, reducing capsaicin-induced pain without opioid side effects.

Alkaline water treatment of grape seed extracts yields urolithin-enriched dry powder.

Antibodies targeting the CSF-1R delD4 fragment inhibit ligand-independent proliferation and osteoclast differentiation.

Procyanidin B1 and B2 mediate active treatment of eosinophilic esophagitis, reducing inflammatory cell infiltration beyond dietary allergen avoidance.

Stromal vascular fraction cells enhance transplanted tissue vascularization, resolving the trade-off between rapid implantation and sufficient blood supply.

Combining a selective PDE4 inhibitor with cyclosporine A reduces inflammation and adverse reactions by synergistically blocking TNF-alpha release.

Chimeric Ig alpha and beta transgenes drive humanized antibody production in non-human animals.

A leukapheresis column removes activated leukocytes from blood using specific antibodies.

A water-in-oil pharmaceutical composition uses a composite surfactant system to maintain homogeneity and prevent phase separation.

Chiral oligoetherpolyol conjugates suppress ATP-ase activity and reduce cytotoxicity while inhibiting P-glycoprotein reverse transport.

A fasting-mimicking diet regimen enhances beneficial gut microbiota expansion through controlled nutritional conditioning.

Administering momelotinib alongside BET protein inhibitors reduces myelosuppression while enhancing anemia benefits through coordinated pathway modulation.

Apoptotic cell compositions mitigate cytokine release syndrome severity by reducing pro-inflammatory production during sepsis therapy.

Engineered IgG1 antibodies with specific amino acid modifications enhance binding affinity to the FcRn receptor.

Modified n-3 PUFA metabolites overcome soluble epoxide hydrolase deactivation and auto-oxidation to enhance stability for treating inflammation.

Modifying amino acid sequences in antibody variable regions blocks CD70-CD27 interactions to overcome insufficient cytotoxicity induction.

A cyclic synthetic peptide binds the human CD154 active site to block CD40 receptor engagement.

Delipidation and affinity purification remove interfering substances from autoimmune samples, ensuring reliable neutralizing antibody assay results.

Engineered antibody polypeptides antagonize CD40 without agonist activity, resolving unwanted T cell activation while treating inflammatory bowel disease.

Fluorous copolymer coatings enable low-temperature deposition of biocompatible surfaces on implantable medical devices.

Composite herbal extracts inhibit influenza virus and modulate immune function, avoiding side effects of conventional drugs.

Itaconate monoesters modulate the NRF2 pathway to reduce cytokine release, addressing rapid hydrolysis limitations of dimethyl fumarate.

A nutraceutical composition combines palmitoylethanolamide, maritime pine extract, and hemp seed oil to deliver synergistic anti-inflammatory action.

Chidamide reactivates latent herpesvirus genes, allowing ganciclovir to eliminate infections previously resistant to standard antiviral therapy.

Human framework regions reduce immunogenicity in anti-BTLA antibodies while preserving binding affinity for therapeutic use.

Humanized anti-CD20 antibodies reduce immunogenicity by grafting human framework sequences onto murine CDR regions while maintaining therapeutic efficacy.

Anti-EGFR antibody conjugates deliver maytansinoid cytotoxic agents to tumor cells via stable linkers, reducing systemic toxicity.

Isotopic substitution of hydrogen with deuterium at metabolic hotspots reduces clearance rates and extends plasma half-life for peptide boronic acid inhibitors.

Nighttime GABAB upregulator administration normalizes sleep architecture and enhances wakeful cognitive performance despite limited existing treatment options.

Self-assembling monomers resolve the molecular weight versus binding specificity trade-off by forming stable multimers that disrupt protein interactions.

Agents with SRCR domain 1 binding specificity deliver therapeutics to macrophages via CD163 receptor endocytosis.

Segmented polymeric materials create tailored diffusion pathways that minimize residual drug entrapment while maintaining extended release duration.